Real-world effectiveness and safety of lasmiditan in patients with migraine: an observational study.

Lasmiditan is a medication used for treating migraines. This study looked at its effectiveness and safety in real-world settings. Researchers assessed 75 migraine patients, mostly women, aged about 44 years. Among them, 35.1% had chronic migraines. Patients filled out questionnaires about their headaches before and after taking lasmiditan. Headache severity was measured using a numerical rating scale. The results showed that 76% of patients experienced relief. Improvement in headache severity occurred in 61.3% of attacks after 2 hours. After 24 hours, 73% reported improvement. Additionally, headache resolution was noted in 27.8% of attacks at 2 hours and 43.9% at 24 hours. Some patients experienced side effects like drowsiness, weakness, and dizziness. Overall, lasmiditan showed promising results for migraine relief, with many patients reporting significant improvement. Clinical relevance: This research indicates that lasmiditan is effective for migraine relief in real-world settings, providing valuable treatment options for patients experiencing migraines.